Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

Journal of clinical pharmacology - 1 Aug 2004

Paoluzzi Luca, Singh Arun S, Price Douglas K, Danesi Romano, Mathijssen Ron H J, Verweij Jaap, Figg William D, Sparreboom Alex

Abstract excerpt

The uridine diphosphate glucuronosyltransferase (UGT) 1A1 and 1A9 isoforms are involved in the phase II biotransformation of the irinotecan metabolite, SN-38. Recently, several variants in the UGT1A1 and UGT1A9 genes have been described with altered functionality in vitro. The aim of this study was to evaluate the functional consequence of the UGT1A1(TA)(7)TAA (UGT1A1(*)28), UGT1A9 766G>A (D256N; UGT1A9(*)5), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Gene Frequency

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasms

Share to UDP-Glucuronosyltransferase 1A9

Source

Identifiers

PMID: 15286088
DOI: 10.1177/0091270004267159

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.PMID 15286088Read ↗

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.Semantic proximity Read ↗

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.Semantic proximity Read ↗

Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.Semantic proximity Read ↗

The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.Semantic proximity Read ↗

<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practiceSemantic proximity Read ↗

Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.Semantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.Semantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.